Clovis Oncology ($CLVS) has signed a deal to test whether its lead drug can make a difference in lung cancer when paired with GlaxoSmithKline's ($GSK) melanoma treatment Mekinist. Under the agreement, the pair will study Clovis' rociletinib (CO-1686) in tandem with GSK's drug, approved last year, in patients with EGFR-mutant non-small cell lung cancer. The Phase I/II study is slated to begin in the first half of next year, the companies said. Clovis' drug has already received the FDA's breakthrough therapy designation for its potential as a monotherapy for NSCLC. The company is racing with AstraZeneca ($AZN) and its similar AZD9291, which the U.K. drugmaker intends to file in the second quarter of 2015. More